<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01465022</url>
  </required_header>
  <id_info>
    <org_study_id>03-151</org_study_id>
    <nct_id>NCT01465022</nct_id>
  </id_info>
  <brief_title>Breastfeeding and Oral Contraceptives: a Randomized, Controlled Trial</brief_title>
  <official_title>Breastfeeding and Oral Contraceptives: a Randomized, Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of New Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American College of Obstetricians and Gynecologists</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of New Mexico</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objectives

      To clarify the relationship between postpartum (2 weeks) use of progestin-only vs. combined
      oral contraceptive pills and the outcomes of breastfeeding continuation, infant growth,
      contraceptive method continuation, and pregnancy rates in breastfeeding women. Specific
      research questions:

        1. To determine whether there is a difference in rates of breastfeeding continuation at 2
           months and 4 months between postpartum breastfeeding women using progestin-only pills
           vs. combined pills.

        2. To determine whether there is a difference in infant growth at 2 weeks and 8 weeks
           between postpartum breastfeeding women using progestin-only pills vs. combined pills.

        3. To determine whether there is a difference in birth control method continuation at 2
           months and 4 months between postpartum breastfeeding women using progestin-only pills
           vs. combined pills.

      Hypothesis

      Combined oral contraceptive pills, when initiated by postpartum breastfeeding women, will
      cause a differential in continuation of breastfeeding: 35% continuation in the combined pill
      group vs. 60% in the progestin-only pill group at 8 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Continued to Breastfeed at 6 Months</measure>
    <time_frame>Baseline to Week 8, Week 8, 2-6 months</time_frame>
    <description>Proportion of participants who are continuing to breastfeed from 2 months to 6 months after delivery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Continued Birth Control Method After 6 Months</measure>
    <time_frame>Baseline to Week 8, Week 8, 2-6 months</time_frame>
    <description>Proportion of participants who are continuing to use either combined estrogen-progestin pill or progestin-only pill up to 6 months after delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infant Length Growth From 2-8 Weeks</measure>
    <time_frame>Week 2 and Week 8</time_frame>
    <description>Comparison of infant length at 2 weeks and 8 weeks between postpartum breastfeeding women using progestin-only pills vs. combined pills. Inclusion criteria of mother's who are actively breastfeeding.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infant Weight Growth From 2-8 Weeks</measure>
    <time_frame>Week 2 and Week 8</time_frame>
    <description>Comparison of infant growth at 2 weeks and 8 weeks between postpartum breastfeeding women using progestin-only pills vs. combined pills. Inclusion criteria of mother's who are actively breastfeeding.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infant Occipitofrontal Circumference Growth From 2-8 Weeks</measure>
    <time_frame>Week 2 and Week 8</time_frame>
    <description>Comparison of infant growth at 2 weeks and 8 weeks between postpartum breastfeeding women using progestin-only pills vs. combined pills. Inclusion criteria of mother's who are actively breastfeeding.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">197</enrollment>
  <condition>Breast Feeding</condition>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>Study Arm A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Study Arm A is one of two interventions (Combined estrogen-progestin pill)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study Arm B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Study Arm B is one of two interventions (Progestin-only pill)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combined estrogen-progestin pill</intervention_name>
    <description>1 mg norethindrone and .035 mg ethinyl estradiol orally for 21 days followed by 7 days of placebo</description>
    <arm_group_label>Study Arm A</arm_group_label>
    <other_name>OCP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Progestin-only pill</intervention_name>
    <description>.35 mg norethindrone once a day orally</description>
    <arm_group_label>Study Arm B</arm_group_label>
    <other_name>POP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  able to give informed consent

          -  postpartum women delivering at the University of New Mexico Hospital

          -  Intend to breastfeed

          -  Plan to use oral contraceptives as her family planning method

          -  Willing to be randomized to either progestin-only pills or combined pills

        Exclusion Criteria:

          -  medical contraindications to combined pills including history of thromboembolism,
             uncontrolled hypertension or complex migraine headaches

          -  preterm birth (&lt;37 weeks)

          -  small for gestational age infant (&lt;2500 grams)

          -  large for gestational age infant (&gt;4500 grams)

          -  infant with major congenital anomaly
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eve Espey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UNM OB Gyn</affiliation>
  </overall_official>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 2011</study_first_submitted>
  <study_first_submitted_qc>November 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2011</study_first_posted>
  <results_first_submitted>May 29, 2015</results_first_submitted>
  <results_first_submitted_qc>December 2, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 15, 2016</results_first_posted>
  <last_update_submitted>April 14, 2016</last_update_submitted>
  <last_update_submitted_qc>April 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of New Mexico</investigator_affiliation>
    <investigator_full_name>Eve Espey</investigator_full_name>
    <investigator_title>Professor, OB-GYN</investigator_title>
  </responsible_party>
  <keyword>Breastfeeding rates</keyword>
  <keyword>Contraceptive continuation</keyword>
  <keyword>Birth control pills</keyword>
  <keyword>Lactation</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Estrogens</mesh_term>
    <mesh_term>Contraceptives, Oral</mesh_term>
    <mesh_term>Progestins</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study design is double-blind randomized controlled trial in which postpartum women who have decided to breastfeed and who choose birth control pills as their contraceptive method are randomized to one of two groups:</recruitment_details>
      <pre_assignment_details>The research nurse recruiting the eligible subject will ask the subject if they have been given adequate time to make a decision regarding study participation.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Combined Estrogen-progestin Pill</title>
          <description>Study Arm A is one of two interventions.</description>
        </group>
        <group group_id="P2">
          <title>Progestin-only Pill</title>
          <description>Study Arm B is one of two interventions.</description>
        </group>
        <group group_id="P3">
          <title>Not Randomized</title>
          <description>Participants who were consented but not randomized.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
                <participants group_id="P2" count="63"/>
                <participants group_id="P3" count="70"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="70"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Breastfeeding discontinuation before 8 w</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not Randomized</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="70"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Combined Estrogen-progestin Pill</title>
          <description>Study Arm A is one of two interventions (OCP).</description>
        </group>
        <group group_id="B2">
          <title>Progestin-only Pill</title>
          <description>Study Arm B is one of two interventions (POP).</description>
        </group>
        <group group_id="B3">
          <title>Not Randomized</title>
          <description>70 women who were enrolled.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="64"/>
            <count group_id="B2" value="63"/>
            <count group_id="B3" value="70"/>
            <count group_id="B4" value="197"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="70"/>
                    <measurement group_id="B4" value="197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.8" spread="4.4"/>
                    <measurement group_id="B2" value="25.0" spread="5.4"/>
                    <measurement group_id="B3" value="23.4" spread="5.0"/>
                    <measurement group_id="B4" value="24.4" spread="197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="70"/>
                    <measurement group_id="B4" value="197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="70"/>
                    <measurement group_id="B4" value="197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Continued to Breastfeed at 6 Months</title>
        <description>Proportion of participants who are continuing to breastfeed from 2 months to 6 months after delivery</description>
        <time_frame>Baseline to Week 8, Week 8, 2-6 months</time_frame>
        <population>Participants available for follow-up through a 6 month period</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Estrogen-progestin Pill</title>
            <description>Study Arm A is one of two interventions (Combined estrogen-progestin pill)
Combined estrogen-progestin pill: 1 mg norethindrone and .035 mg ethinyl estradiol orally for 21 days followed by 7 days of placebo</description>
          </group>
          <group group_id="O2">
            <title>Progestin-only Pill</title>
            <description>Study Arm B is one of two interventions (Progestin-only pill)
Progestin-only pill: .35 mg norethindrone once a day orally</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Continued to Breastfeed at 6 Months</title>
          <description>Proportion of participants who are continuing to breastfeed from 2 months to 6 months after delivery</description>
          <population>Participants available for follow-up through a 6 month period</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Particpants lost to follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinued Breastfeeding prior to 8 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title># of participants included in 8 week follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinued breastfeeding between 2-6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants available for follow-up at 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Continued Birth Control Method After 6 Months</title>
        <description>Proportion of participants who are continuing to use either combined estrogen-progestin pill or progestin-only pill up to 6 months after delivery</description>
        <time_frame>Baseline to Week 8, Week 8, 2-6 months</time_frame>
        <population>Participants available for follow-up through a 6 month period</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Estrogen-progestin Pill</title>
            <description>Study Arm A is one of two interventions (Combined estrogen-progestin pill)
Combined estrogen-progestin pill: 1 mg norethindrone and .035 mg ethinyl estradiol orally for 21 days followed by 7 days of placebo</description>
          </group>
          <group group_id="O2">
            <title>Progestin-only Pill</title>
            <description>Study Arm B is one of two interventions (Progestin-only pill)
Progestin-only pill: .35 mg norethindrone once a day orally</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Continued Birth Control Method After 6 Months</title>
          <description>Proportion of participants who are continuing to use either combined estrogen-progestin pill or progestin-only pill up to 6 months after delivery</description>
          <population>Participants available for follow-up through a 6 month period</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Particpants lost to follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinued oral contraceptives by 8 week mark</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants available for follow-up at 8 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinued oral contraceptives from 2-6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants available for follow-up at 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Infant Length Growth From 2-8 Weeks</title>
        <description>Comparison of infant length at 2 weeks and 8 weeks between postpartum breastfeeding women using progestin-only pills vs. combined pills. Inclusion criteria of mother's who are actively breastfeeding.</description>
        <time_frame>Week 2 and Week 8</time_frame>
        <population>At 2 week point 64 participants for follow-up in combined pills arm, 63 for follow-up in progestin-only pills arm.
At 8 week point 41 participants for follow-up in combined pills arm, 40 for follow-up in progestin-only pills arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Estrogen-progestin Pill</title>
            <description>Study Arm A is one of two interventions (Combined estrogen-progestin pill)
Combined estrogen-progestin pill: 1 mg norethindrone and .035 mg ethinyl estradiol orally for 21 days followed by 7 days of placebo</description>
          </group>
          <group group_id="O2">
            <title>Progestin-only Pill</title>
            <description>Study Arm B is one of two interventions (Progestin-only pill)
Progestin-only pill: .35 mg norethindrone once a day orally</description>
          </group>
        </group_list>
        <measure>
          <title>Infant Length Growth From 2-8 Weeks</title>
          <description>Comparison of infant length at 2 weeks and 8 weeks between postpartum breastfeeding women using progestin-only pills vs. combined pills. Inclusion criteria of mother's who are actively breastfeeding.</description>
          <population>At 2 week point 64 participants for follow-up in combined pills arm, 63 for follow-up in progestin-only pills arm.
At 8 week point 41 participants for follow-up in combined pills arm, 40 for follow-up in progestin-only pills arm.</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mean Infant length at 2 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.5" spread=".49"/>
                    <measurement group_id="O2" value="51.7" spread=".49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean Infant length at 8 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.8" spread=".49"/>
                    <measurement group_id="O2" value="57" spread=".49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Infant Weight Growth From 2-8 Weeks</title>
        <description>Comparison of infant growth at 2 weeks and 8 weeks between postpartum breastfeeding women using progestin-only pills vs. combined pills. Inclusion criteria of mother's who are actively breastfeeding.</description>
        <time_frame>Week 2 and Week 8</time_frame>
        <population>At 2 week point 64 participants for follow-up in combined pills arm, 63 for follow-up in progestin-only pills arm.
At 8 week point 41 participants for follow-up in combined pills arm, 40 for follow-up in progestin-only pills arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Estrogen-progestin Pill</title>
            <description>Study Arm A is one of two interventions (Combined estrogen-progestin pill)
Combined estrogen-progestin pill: 1 mg norethindrone and .035 mg ethinyl estradiol orally for 21 days followed by 7 days of placebo</description>
          </group>
          <group group_id="O2">
            <title>Progestin-only Pill</title>
            <description>Study Arm B is one of two interventions (Progestin-only pill)
Progestin-only pill: .35 mg norethindrone once a day orally</description>
          </group>
        </group_list>
        <measure>
          <title>Infant Weight Growth From 2-8 Weeks</title>
          <description>Comparison of infant growth at 2 weeks and 8 weeks between postpartum breastfeeding women using progestin-only pills vs. combined pills. Inclusion criteria of mother's who are actively breastfeeding.</description>
          <population>At 2 week point 64 participants for follow-up in combined pills arm, 63 for follow-up in progestin-only pills arm.
At 8 week point 41 participants for follow-up in combined pills arm, 40 for follow-up in progestin-only pills arm.</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mean Infant weight at 2 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" spread=".36"/>
                    <measurement group_id="O2" value="3.7" spread=".36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean infant weight at 8 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.08" spread=".36"/>
                    <measurement group_id="O2" value="5.2" spread=".36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Infant Occipitofrontal Circumference Growth From 2-8 Weeks</title>
        <description>Comparison of infant growth at 2 weeks and 8 weeks between postpartum breastfeeding women using progestin-only pills vs. combined pills. Inclusion criteria of mother's who are actively breastfeeding.</description>
        <time_frame>Week 2 and Week 8</time_frame>
        <population>At 2 week point 64 participants for follow-up in combined pills arm, 63 for follow-up in progestin-only pills arm.
At 8 week point 41 participants for follow-up in combined pills arm, 40 for follow-up in progestin-only pills arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Estrogen-progestin Pill</title>
            <description>Study Arm A is one of two interventions (Combined estrogen-progestin pill)
Combined estrogen-progestin pill: 1 mg norethindrone and .035 mg ethinyl estradiol orally for 21 days followed by 7 days of placebo</description>
          </group>
          <group group_id="O2">
            <title>Progestin-only Pill</title>
            <description>Study Arm B is one of two interventions (Progestin-only pill)
Progestin-only pill: .35 mg norethindrone once a day orally</description>
          </group>
        </group_list>
        <measure>
          <title>Infant Occipitofrontal Circumference Growth From 2-8 Weeks</title>
          <description>Comparison of infant growth at 2 weeks and 8 weeks between postpartum breastfeeding women using progestin-only pills vs. combined pills. Inclusion criteria of mother's who are actively breastfeeding.</description>
          <population>At 2 week point 64 participants for follow-up in combined pills arm, 63 for follow-up in progestin-only pills arm.
At 8 week point 41 participants for follow-up in combined pills arm, 40 for follow-up in progestin-only pills arm.</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Infant occipitofrontal circumference at 2 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36" spread=".84"/>
                    <measurement group_id="O2" value="36.1" spread=".84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infant occipitofrontal circumference at 8 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39" spread=".84"/>
                    <measurement group_id="O2" value="39" spread=".84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 years - no adverse events reported</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Combined Estrogin-progestin Pill</title>
          <description>Study Arm A is one of two interventions (Combined estrogen-progestin pill)
Combined estrogen-progestin pill: 1 mg norethindrone and .035 mg ethinyl estradiol orally for 21 days followed by 7 days of placebo</description>
        </group>
        <group group_id="E2">
          <title>Progestin-only Pill</title>
          <description>Study Arm B is one of two interventions (Progestin-only pill)
Progestin-only pill: .35 mg norethindrone once a day orally</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Eve Espey MD, MPH, Principal Investigator</name_or_title>
      <organization>University of New Mexico</organization>
      <phone>505 272 6372</phone>
      <email>eespey@salud.unm.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

